· 2022 ICD-10-CM Diagnosis Code Z92.21 Personal history of antineoplastic chemotherapy 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code POA Exempt Z92.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z92.21 became effective on October 1, 2021.
ICD-10-CM Diagnosis Code Z92.21 [convert to ICD-9-CM] Personal history of antineoplastic chemotherapy. H/o: chemotherapy; History of anti-cancer chemotherapy; History of antineoplastic chemotherapy; History of chemotherapy. ICD-10-CM Diagnosis Code Z92.21. Personal history of antineoplastic chemotherapy.
Z92.21 is a billable diagnosis code used to specify a medical diagnosis of personal history of antineoplastic chemotherapy. The code Z92.21 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions. The ICD-10-CM code Z92.21 might also be used to specify conditions or terms like h/o: …
· Z92.21 is a valid billable ICD-10 diagnosis code for Personal history of antineoplastic chemotherapy . It is found in the 2022 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 . POA Exempt Z92.21 is exempt from POA reporting ( Present On Admission).
ICD-10 code Z92. 21 for Personal history of antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
When a patient's cancer is successfully treated and there is no evidence of the disease and the patient is no longer receiving treatment, use Z85, “Personal history of malignant neoplasm.” Update the problem list and use this history code for surveillance visits and annual exams.
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Z76. 89 is a billable diagnosis code used to specify a medical diagnosis of persons encountering health services in other specified circumstances.
Personal history of malignant neoplasm, unspecified Z85. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z85. 9 became effective on October 1, 2021.
In-active neoplasm or cancer is coded when a patient is no longer receiving treatment for cancer and the cancer is in remission by using the V “history of” code (“Z” code for ICD-10).
If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy assign code Z51. 0, Encounter for antineoplastic radiation therapy, or Z51. 11, Encounter for antineoplastic chemotherapy, or Z51.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
Encounter for antineoplastic immunotherapy2022 ICD-10-CM Diagnosis Code Z51. 12: Encounter for antineoplastic immunotherapy.
Persons encountering health services in other specified circumstancesICD-10 code Z76. 89 for Persons encountering health services in other specified circumstances is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Z76. 89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
9: Person encountering health services in unspecified circumstances.
Personal history codes may be used in conjunction with follow-up codes and family history codes may be used in conjunction with screening codes to explain the need for a test or procedure. History codes are also acceptable on any medical record regardless of the reason for visit.
(PER-suh-nul HIH-stuh-ree) A collection of information about a person's health that allows the person to manage and track his or her own health information. A personal history may include information about allergies, illnesses, surgeries, immunizations, and results of physical exams, tests, and screenings.
Personal history of malignant neoplasm of breastZ85. 3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.The 2022 edition of ICD-10-CM Z85. 3 became effective on October 1, 2021.This is the American ICD-10-CM version of Z85.
If the site of the primary cancer is not documented, the coder will assign a code for the metastasis first, followed by C80. 1 malignant (primary) neoplasm, unspecified. For example, if the patient was being treated for metastatic bone cancer, but the primary malignancy site is not documented, assign C79. 51, C80.
Z92.21 is a billable diagnosis code used to specify a medical diagnosis of personal history of antineoplastic chemotherapy. The code Z92.21 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.#N#The ICD-10-CM code Z92.21 might also be used to specify conditions or terms like h/o: chemotherapy, h/o: high risk medication or history of antineoplastic chemotherapy. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.#N#The code Z92.21 describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth.
You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss.
Z92.21 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.
Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away. Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments.
The 2022 edition of ICD-10-CM Z87.19 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
g. Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms
When the reason for admission/encounter is to determine the extent of the malignancy, or for a procedure such as paracentesis or thoracentesis, the primary malignancy or appropriate metastatic site is designated as the principal or first-listed diagnosis, even though chemotherapy or radiotherapy is administered.
The 2022 edition of ICD-10-CM Z86.19 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
The 2022 edition of ICD-10-CM Z92.3 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status
The 2022 edition of ICD-10-CM Z86.69 became effective on October 1, 2021.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status